By modifying the drug release characteristics, significant therapeutic benefits can be achieved, such as improved efficacy of the therapeutic agent, reduced adverse effects, optimization of the dosing scheme, and overall improvement in patient compliance. There are numerous approaches for modified release, each with its own benefits and drawbacks. This webinar will present PVA, a fully-synthetic polymer, for optimized sustained release matrix formulations. Combining robust and reliable gel-forming behavior with optimized tableting properties, PVA provides solutions for the most challenging sustained release formulations.
In this webinar, you will learn:
- How the gel-formation properties of PVA introduce sustained release
- Why compatibility with direct compression leads to simplified formulations
- That PVA can provide flexibility in sustained release formulation development
Speaker
Gudrun Birk, Ph.D.
Merck
Laboratory Head Controlled Release
Gudrun Birk is a pharmacist by education and has been with Merck since 2014. She completed her Ph.D. in pharmaceutical formulation development in the field of parenteral applications in our biopharma business in cooperation with the University of Munich. Within her current R&D role, Gudrun focuses on the development of innovative new excipients and functional excipient systems for solid oral dosage forms. Inorganic drug carriers for solubility enhancement of APIs is one of her main areas of expertise, spanning from scientific basic research to industrial product development.
Pharma and biopharma manufacturing
- Pharma and biopharma manufacturing
期間:53min
言語:English
セッション 1:presented August 20, 2020
続きを確認するには、ログインするか、新規登録が必要です。
アカウントをお持ちではありませんか？